BioGenes brings latest immunogenicity and PK testing tools to BIO International
Press Release | BioGenes GmbH
MAY 24, 2018
Berlin, Germany: – Leading force in host cell protein (HCP) assay development, BioGenes GmbH, will bring its latest immunogenicity and PK testing tools to Boston for the upcoming 25th Anniversary BIO International Convention, one of the biggest biotech industry events in the world.
BioGenes will be an exhibitor at the event with a stand at Booth 1601-2 as part of the German Pavilion at the Boston Convention and Exhibition Center (BCEC). Its team in Boston will be headed by Managing Director, Dr. Alexander Knoll.
Immunogenicity and PK testing expertise
The BioGenes display will showcase its complete panel of services and solutions that include custom antibody development (pAbs, mAbs, anti-IDs), custom ELISA development and kit production, Host Cell Protein (HCP) assays and analytical services.
The BioGenes display will particularly focus on the company’s recently developed Immunogenicity and pharmacokinetic (PK) testing tools and services. These include custom development of Immunogenicity-and PK assays as well as corresponding antibodies.
“We are delighted to be returning to BIO International for an 18th successive year,” said BioGenes Marketing & Sales Director, Dagmar Schwertner-Knoll.
“BIO International is one of the most important networking and knowledge-sharing events for our industry and a great platform for making new contacts and sharing information on the latest trends in testing of new therapeutics, biologics and biosimilars,” she added.
About BioGenes GmbH
BioGenes GmbH (BioGenes) is an acknowledged global leader in host cell protein (HCP) assay development and a recognized partner of pharmaceutical companies all over the world. The Berlin-based company specializes in highly sophisticated and customized antibody and immunoassay development and is an experienced and reliable partner for process development improvements in all areas of quality control, diagnostics and drug discovery.
BioGenes is known as a trusted and experienced expert in immunoassay, 2D electrophoresis and antibody development with a business strategy focused on driving forward innovations for customers and building new strategic partnerships aimed at cementing its market leadership in host cell assay development.
BioGenes was founded in 1992 by Dr. Alexander Knoll (Managing Director) and Dr. Sergej Ovodov (Scientific Director), who are now sole owners following a management buyout in October 2015. Headquartered in Berlin, the company has a workforce numbering more than 50 people, most of them scientists.
The company maintains long-term relationships with research institutes, universities and biotech and pharmaceutical companies, including eight of the ten largest pharmaceutical companies in the world.
About BIO International 2018
The 25th Anniversary BIO International Convention (BIO) provides a week of intensive networking for biotechnology and pharma leaders to discover new opportunities and promising partnerships. It attracts more than 16,000 delegates involved in a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.
BIO International 2018 returns to Boston MA as a four -day event opening June 4 at the waterfront Boston Convention and Exhibition Center (BCEC). The convention will feature more than 35,000 face-to-face meetings for some 3,100 companies organised using the proprietary BIO One-on-One partnering™ system, as well as hundreds of individual company presentations, a program of world-renowned keynote speakers and some 20 Session Tracks.
A co-located trade show will feature more than 1,800 exhibitors from fields ranging from digital health and diagnostics to bioprocesses.
The event is organized by the Washington DC-based Biotechnology Innovation Organization with more information at: http://convention.bio.org/.
Dagmar Schwertner-Knoll, Marketing & Sales Director, BioGenes GmbH
Tel: +49 30 6576 2396